We are live on ! Find out more
HUMA icon

Humacyte

69 hedge funds and large institutions have $37.4M invested in Humacyte in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more call options, than puts

Call options by funds: $152K | Put options by funds: $41K

49% more capital invested

Capital invested by funds: $25.1M → $37.4M (+$12.4M)

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

0.08% more ownership

Funds ownership: 11.59%11.67% (+0.08%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less funds holding

Funds holding: 7569 (-6)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

Holders
69
Holders Change
-6
Holders Change %
-8%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
23
Reduced
18
Closed
18
Calls
$152K
Puts
$41K
Net Calls
+$111K
Net Calls Change
+$113K

HUMA Hedge Fund Activity: Q1 2023 in Review

69 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2023, worth a combined $37.4M — up 49% from $25.1M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of HUMA and 12 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 23 added.

The largest buyer was Geode Capital Management, adding an estimated $508K. The largest seller was BlackRock, cutting an estimated $589K.

  • 69 institutional investors held Humacyte (HUMA) as of Q1 2023, down from 75 in Q4 2022.
  • Funds reported $37.4M of Humacyte stock for Q1 2023, up 49% quarter-over-quarter.
  • 12 funds opened new Humacyte positions in Q1 2023 and 18 closed out, a net change of -6 holders.
  • The largest Humacyte buyer in Q1 2023 was Geode Capital Management, an estimated $508K added.
  • The largest Humacyte seller in Q1 2023 was BlackRock, an estimated $589K sold.

Based on aggregated 13F filings for Q1 2023.